SCHEMBL3606938

SCHEMBL3606938

Cc1c(C(=O)O)oc2cccc(NS(=O)(=O)c3ccccc3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
GAA P10253 3/20 0.51
HTT P42858 1/20 0.51
MMP2 P08253 4/20 0.50
MMP13 P45452 3/20 0.50
EDNRA P25101 2/20 0.50
ADAMTS4 O75173 1/20 0.50
MMP9 P14780 1/20 0.50
MMP14 P50281 1/20 0.50
METAP2 P50579 1/20 0.48
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TSHR P16473 1/20 0.46
PGAM1 P18669 1/20 0.46
MCL1 Q07820 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599237 0.86 TSHR (0.61) ALDH1A1GAAHTTKMT2AHPGD
SCHEMBL3614760 0.85 EDNRA (0.54) GAAMMP2MMP13EDNRAADAMTS4
SCHEMBL3609578 0.83 EDNRA (0.51) GAAMMP2MMP13EDNRAADAMTS4
SCHEMBL3616881 0.82 ALDH1A1 (0.55) ALDH1A1GAAHTTEDNRAKMT2A
SCHEMBL3619986 0.82 EDNRA (0.50) GAAMMP2MMP13EDNRAADAMTS4
SCHEMBL12610891 0.82 KMT2A (0.52) ALDH1A1GAAHTTMMP2METAP2
SCHEMBL3621352 0.79 EDNRA (0.59) ALDH1A1MMP2MMP13EDNRAKMT2A
SCHEMBL3613950 0.76 EDNRA (0.50) ALDH1A1GAAMMP2MMP13EDNRA
SCHEMBL3604101 0.76 EDNRA (0.56) ALDH1A1MMP2MMP13EDNRAKMT2A
SCHEMBL3617468 0.75 EDNRA (0.49) ALDH1A1GAAMMP2MMP13EDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same WYETH (US) 2010-06-03 US disclosed
EP-1692124-B1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH CORP (US) 2008-10-15 EP disclosed
US-7420001-B2 Biaryl sulfonamides and methods for using same WYETH (US) 2008-09-02 US disclosed
EP-1692124-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS Wyeth (US) 2006-08-23 EP disclosed
WO-2005061477-A1 BIARYL SULFONAMIDES AS MMP INHIBITORS WYETH (US) 2005-07-07 WO disclosed
US-20050143422-A1 Biaryl sulfonamides and methods for using same WYETH (US) 2005-06-30 US disclosed
CN-1623537-A Biaryl sulfonamides and its using method WYETH CORP (US) 2005-06-08 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137298-A1 Biaryl Sulfonamides and Methods for Using Same STS, MMP3, AADAC ALDH1A1 634/4885GAA 161/4885HTT 4134/4885
US-20050143422-A1 Biaryl sulfonamides and methods for using same STS, MMP3, AADAC ALDH1A1 634/4885GAA 161/4885HTT 4134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.